Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
413.81
-8.43 (-2.00%)
After Hours: 416.00 +2.19 (0.53%)
Apr 1, 7:31PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 407.55 - 423.47
52 week 272.02 - 480.18
Open 423.20
Vol / Avg. 2.71M/2.02M
Mkt cap 99.06B
P/E 33.42
Div/yield     -
EPS 12.38
Shares 234.56M
Beta 1.02
Inst. own 92%
Jun 12, 2015
Biogen Idec Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Apr 21, 2015
Q1 2015 Biogen Idec Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 2, 2015
Biogen Idec Inc at Cowen Health Care Conference
Feb 25, 2015
Biogen Idec Inc at RBC Healthcare Conference - Webcast
Jan 29, 2015
Q4 2014 Biogen Idec Inc Earnings Call - Webcast
Jan 29, 2015
Q4 2014 Biogen Idec Inc Earnings Release
Jan 12, 2015
Biogen Idec Inc at JPMorgan Healthcare Conference - Q&A
Jan 12, 2015
Biogen Idec Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 33.43% 30.47%
Operating margin 43.92% 40.94%
EBITD margin - 47.46%
Return on average assets 25.27% 22.59%
Return on average equity 33.37% 30.21%
Employees 7,550 -
CDP Score - 81 C

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc., formerly Biogen Idec Inc., is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed treatments for relapsing forms of multiple sclerosis (MS). AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and to treat Crohn�s disease. The Company�s RITUXAN is a monoclonal antibody therapeutic used to treat non-Hodgkin�s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia among others. FAMPYRA addresses the need of walking improvement in adult patients with MS who have walking disability and for the treatment of psoriasis.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Pharmaceutical Operations and Technology
Age: 52
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 60
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology and Business Solutions
Age: 52
Bio & Compensation  - Reuters
Tony Kingsley Executive Vice President - Global Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 56
Bio & Compensation  - Reuters